Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness

Journal of the American Pharmacists Association

Volumn 56, Issue 1, 2016, Pages 14-21

  Klepser, Michael E ^a   Klepser, Donald G ^b   Dering Anderson, Allison M ^b   Morse, Jacqueline A ^c   Smith, Jaclyn K ^b   Klepser, Stephanie A ^d  

^a FERRIS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Meijer Pharmacy ^*  (United States)

^d Clinical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIAGNOSTIC TEST; FLU LIKE SYNDROME; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE FACILITY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NOSE SMEAR; PHARMACIST; PHARMACY; PHYSICIAN; POINT OF CARE TESTING; PROSPECTIVE STUDY; RAPID INFLUENZA DIAGNOSTIC TEST; RAPID TEST; SCREENING; SEASONAL INFLUENZA; CLINICAL TRIAL; COOPERATION; DISEASE MANAGEMENT; FEMALE; INFLUENZA, HUMAN; MALE; MICHIGAN; MIDDLE AGED; MINNESOTA; MULTICENTER STUDY; NEBRASKA; ORGANIZATION AND MANAGEMENT; PROGRAM EVALUATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COMMUNITY PHARMACY SERVICES; COOPERATIVE BEHAVIOR; DISEASE MANAGEMENT; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MICHIGAN; MIDDLE AGED; MINNESOTA; NEBRASKA; PHARMACISTS; PHYSICIANS; PROGRAM EVALUATION; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84958721570     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1016/j.japh.2015.11.008     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenzadUnited States, 1976-2007. MMWR Weekly. 2010;59(33):1057-1062.
2. Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization PracticesdUnited States, 2013-2014. MMWR Recommendations and Reports. 2013;62(RR07):1-43.
3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086-5096.
4. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-1373.
5. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother. 2003;51:123-129.
6. Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014;14:109-118.
7. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-1672.
8. Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med. 2008;10:131.
9. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009;124:170-178.
10. Dugas AF, Valsamakis A, Atreya MR, et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med. Available at: http://dx.doi.org/10.1016/j. ajem.2015.03.008. Accessed April 1, 2015.
11. Fiore AE, Fry A, Shay D, Gubareva L, Bresse JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenzadrecommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports. 2011;60(RR01):1-24.
12. Giberson S, Yoder S, Lee MP. Improving patient and health system outcomes through advanced pharmacy practice. A report to the U. S. Surgeon General. Office of the Chief Pharmacist, U. S. Public Health Service; 2011. Available at: http://www.accp. com/docs/positions/misc/improving-patient-and-health-system-outcomes.pdf. Accessed May 3, 2014.
13. Department of Health and Human Services. The adequacy of pharmacist supply: 2004 to 2030. Available at: http://bhpr.hrsa.gov/healthworkforce/supplydemand/pharmacy/pharmsupply20042030.pdf. Accessed April 1, 2015.
14. National Association of Chain Drug Stores. NACDS 2008-2009 Chain pharmacy industry profile. Alexandria, VA: National Association of Chain Drug Stores; 2008.
15. Giberson S, Diak P, Dill G, et al. Pharmacy prevention strategy. U. S. Public Health Service; 2011. Available at: http://www.usphs.gov/corpslinks/pharmacy/documents/PreventionStrategy.pdf. Accessed May 3, 2014.
16. Klepser M, Hagerman J, Klepser D, Klepser S, Bergman S. Evaluation of a community pharmacy-based influenza screening and management program versus pharmacy screening and referral to standard of care. American College of Clinical Pharmacy 2011 Annual Meeting; Pittsburgh, PA.
17. National Association of Chain Drug Stores. Community pharmacybased point-of-care testing certificate program. Available at: http://nacds.learnercommunity.com/course-information. Accessed April 1, 2015.
18. Centers for Disease Control and Prevention. Weekly US map: influenza summary update. Available at: http://www.cdc.gov/flu/weekly/usmap. htm. Accessed April 1, 2015.
19. Quidel Corp. Sofia Influenza A+B FIA product information. Available at: http://www.quidel.com/sites/default/files/product/documents/sofia-hcg-pi-ef1241702en00.pdf. Accessed April 1, 2015.
20. Quidel Corp. QuickVue Influenza A+B Test. Available at: http://www.quidel.com/sites/default/files/product/documents/pi-qvinfluenzaab-waived. pdf. Accessed April 1, 2015.
21. Food and Drug Administration. Proposed reclassification of the rapid influenza detection tests. Available at: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-adcom/documents/document/ucm356185. pdf. Accessed April 1, 2015.
22. Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. J Am Pharm Assoc. 2006;46:168-179.
23. Weitzel KW, Goode JV. Implementation of a pharmacy-based immunization program in a supermarket chain. J Am Pharm Assoc. 2000;40:252-256.
24. Dent LA, Harris KJ, Noonan CW. Tobacco interventions delivered by pharmacists: a summary and systematic review. Pharmacotherapy. 2007;27:1040-1051.
25. Elias MN, Burden AM, Cadarette SM. The impact of pharmacist interventions on osteoporosis management: a systematic review. Osteoporos Int. 2011;22:2587-2596.
26. Snella KA, Canales AE, Irons BK, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2006;46:370-377.
27. Kauffman Y, Nair V, Herist K, Thomas V, Weidle PJ. HIV medication therapy management services in community pharmacies. J Am Pharm Assoc. 2012;52:e287-291.
28. Kuehn BM. CDC pilot program will offer free rapid HIV tests through pharmacies. JAMA. 2012;308:327.
29. Ebell MH, Call M, Shinholser J. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract. 2013;30:125-133.
30. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect. 2011;63:288-294.
31. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010;51:887-894.
32. Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis. 2011;53:277-279.
33. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet. 2014;2:395-404.
34. Torres JP, O'Ryan M, Herve B, et al. Impact of the novel influenza A (H1N1) during the 2009 autumn-winter season in a large hospital setting in Santiago, Chile. Clin Infect Dis. 2010;50:860-868.
35. Blue Cross Blue Shield Massachusetts. Typical costs for common medical services. Available at: http://www.bluecrossma.com/blue-iq/pdfs/Typical Costs-89717-042709.pdf. Accessed September 24, 2014.
36. Klepser D, Dering-Anderson A, Morse J, Klepser M, Klepser S, Corn C. Time and motion study of influenza diagnostic testing in a community pharmacy. Innov Pharm. 2014;5:1-8.
37. Klepser DG, Bisanz SE, Klepser ME. Cost-effectiveness of pharmacistprovided treatment of adult pharyngitis. Am J Manag Care. 2012;18:e145-e154.
38. Havers F, Thaker S, Clippard JR, et al. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis. 2014;59:774-782.
39. Dering-Anderson A, Kilgore P, Hospodka R, Akinwale T. Creating a pharmacist's clinical collaborative practice agreement. Pharmacy tool kit. Available at: http://www.naccho.org/toolbox/tool.cfm?id=4515. Accessed March 4, 2015.
40. Epperson S, Blanton L, Kniss K, et al. Influenza activitydUnited States, 2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Weekly. 2014;63:483-490.